drugset / Trial / NCT05362851

Clinical Trial of YYC301 P3 for Treatment of Osteoarthritis of the Knee

NCT05362851

RandomizedParallel-groupDouble-blindTreatment

Summary

A Multi-center, Double-blinded, Randomized, Active-controlled, Parallel Design, phase 3 Clinical Trial to Evaluate the Efficacy and Safety of YYC301 in Patients with Osteoarthritis of the Knee Joint

Timeline

Start
2021-11-11
Primary completion
2023-01-31
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg
Subject Tramadol Other / unclassified 37.5 mg
Subject Tramadol Other / unclassified 75 mg
Subject Tramadol Other / unclassified 150 mg

Indications